AbbVie, a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that data from two replicate Phase 3 studies evaluating the efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the 13th World Congress on Endometriosis in Vancouver, Canada. New data highlighting the effects of two different elagolix doses and dosing regimens on ovarian sex hormones and ovulation will also be presented.
“Endometriosis is associated with painful symptoms that can be debilitating and there have been few recent medical advancements for women suffering from this disease,” said Rob Scott, M.D., Vice President, Development and Chief Medical Officer, AbbVie. “These results highlight the efficacy and safety profile of elagolix and demonstrate its potential to be an important treatment option for women suffering from endometriosis.”
AbbVie Oral Presentations:
- Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, for the Management of Endometriosis-Associated Pain: Safety and Efficacy Results From Two Double-Blind, Randomized, Placebo-Controlled Studies; Taylor H et al.; Session MS08: Advances in Medical Treatments; Friday, May 19, 2017; 1:15PM to 3:15PM PT
- The Effect of Elagolix on Bone Mineral Density: Safety Results From Two Randomized, Placebo-Controlled Studies in Women With Endometriosis-Associated Pain; Duan W.R., et al.; Session MS08: Advances in Medical Treatments; Friday, May 19, 2017; 1:15PM to 3:15PM PT
- The Effect of Elagolix on the Endometrium: Results From Two Randomized, Placebo-Controlled Studies in Women With Endometriosis-Associated Pain (EAP); Lessey B et al.; Session FC08: Endometrium; Saturday, May20, 2017; 10:45AM to 11:45AM PT
AbbVie Posters:
- Use of Elagolix For the Management of Endometriosis-Associated Pain: Secondary Efficacy Results From Two Randomized, Placebo-Controlled Studies; Taylor H et al.; Poster #PS02-094; Thursday, May 18 and Friday, May 19, 2017; 5:15PM to 6:30PM PT
- Effects of Elagolix, an Oral Gonadotropin-Releasing Hormone (GNRH) Antagonist, on Gonadotropins and Ovarian Sex Hormones in Healthy Premenopausal Women; Ng J et al.; Poster #PS02-003; Thursday, May 18 and Friday, May 19, 2017; 5:15PM to 6:30PM PT
- Effects of Elagolix, an Oral Gonadotropin-Releasing Hormone (GNRH) Antagonist, on Ovulation, Ovarian Activity, and Ovarian Reserve in Healthy Premenopausal Women; Ng J et al.; Poster #PS02-004; Thursday, May 18 and Friday, May 19, 2017; 5:15PM to 6:30PM PT
- The Effect of Elagolix on Estradiol: Results From Two Randomized Phase 3 Studies in Women With Endometriosis-Associated Pain (EAP);Ng J et al.; Poster #PS02-014; Thursday, May 18 and Friday, May 19, 2017; 5:15PM to 6:30PM PT
Filed Under: Drug Discovery
